Cigna earnings beat by $0.04, revenue topped estimates
COPENHAGEN—Heidi Hunter, a director at IO Biotech , Inc. (NASDAQ:IOBT), recently acquired 15,000 shares of the company’s common stock. The transaction took place on May 30, 2025, with a weighted average purchase price of $1.3923 per share, resulting in a total value of approximately $20,884. The purchase comes as the stock shows strong momentum, with a 17% gain in the past week and trading near $1.42. According to InvestingPro data, analysts maintain a bullish outlook with price targets ranging from $6 to $14.
The shares were purchased in multiple trades at prices ranging from $1.37 to $1.40. Following this transaction, Hunter’s direct ownership stands at 15,000 shares. The $93.55 million market cap company maintains a strong balance sheet, with more cash than debt and a healthy current ratio of 2.32.
This acquisition highlights continued interest and investment by company insiders in IO Biotech, which is based in Copenhagen, Denmark. InvestingPro subscribers can access 12 additional investment tips and comprehensive financial metrics to better evaluate this insider purchase.
In other recent news, IO Biotech has shared preclinical data on two therapeutic cancer vaccine candidates at a major cancer research meeting. The data highlighted the potential of their T-win® platform, with one vaccine candidate, IO102-IO103, showing strong T-cell responses in preclinical studies. Meanwhile, the second candidate, IO170, demonstrated significant growth inhibition in breast and prostate cancer models. In addition, H.C. Wainwright maintained a Buy rating and a $12 price target on IO Biotech, noting the company’s updated guidance on their Phase 3 trial for Cylembio. The trial’s primary endpoint data is now expected in the third quarter of 2025 due to a deceleration in progression-free survival events. Furthermore, IO Biotech announced it is on track to submit a Biologics License Application for Cylembio by the end of 2025. Financially, the company ended the fourth quarter of 2024 with $60 million in cash and has secured additional financing from the European Investment Bank.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.